Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – What’s Next?

Shares of Pharvaris N.V. (NASDAQ:PHVS) saw an uptick in trading volume on Tuesday . 413,006 shares changed hands during trading, an increase of 5% from the previous session’s volume of 395,039 shares.The stock last traded at $38.0650 and had previously closed at $38.86.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
• Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
• Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. New Street Research set a $60.00 price objective on shares of Pharvaris in a report on Friday, August 14th. HSBC raised shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Guggenheim boosted their price target on shares of Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. UBS Group set a $79.00 price target on shares of Pharvaris in a research report on Wednesday, September 9th. Finally, Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pharvaris has an average rating of “Moderate Buy” and a consensus target price of $59.87.

Pharvaris Stock Down 1.3%

The stock has a market cap of $2.46 billion, a P/E ratio of -12.31 and a beta of -2.33. The company has a 50-day simple moving average of $35.31 and a two-hundred day simple moving average of $31.63.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts forecast that Pharvaris N.V. will post -3.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Pharvaris

In other Pharvaris news, insider Anne Lesage sold 30,000 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $38.30, for a total value of $1,149,000.00. Following the sale, the insider owned 56,450 shares of the company’s stock, valued at $2,162,035. This trade represents a 34.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $39.40, for a total transaction of $90,265.40. Following the completion of the transaction, the chief executive officer owned 128,334 shares in the company, valued at $5,056,359.60. The trade was a 1.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 212,445 shares of company stock worth $7,882,086 over the last ninety days. 11.84% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Alyeska Investment Group L.P. boosted its holdings in Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock valued at $14,068,000 after acquiring an additional 281,829 shares in the last quarter. BlackRock Inc. bought a new position in Pharvaris in the 2nd quarter worth $26,677,000. Seven Fleet Capital Management LP raised its holdings in Pharvaris by 472.3% in the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock worth $8,947,000 after purchasing an additional 261,355 shares in the last quarter. PSP Research LLC purchased a new stake in shares of Pharvaris in the 4th quarter worth about $569,000. Finally, DV Trading LLC purchased a new stake in shares of Pharvaris in the 1st quarter worth about $4,067,000.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.